Journey Medical (DERM) Stock Price, News & Analysis

Company Overview

Journey Medical Corporation is a specialty pharmaceutical company dedicated to the development, commercialization and licensing of prescription dermatology products. The company focuses on addressing immune-mediated skin disorders and related conditions, offering topical and systemic therapies designed to improve patient outcomes. Since its establishment, Journey Medical has pursued a targeted strategy of in-licensing late-stage assets, completing product approvals and bringing leading dermatology treatments to market in the United States.

Among its approved products, Journey Medical markets a range of corticosteroid and non-corticosteroid formulations for chronic skin diseases. Its flagship therapy provides relief for patients suffering from plaque psoriasis, while other products in its portfolio address conditions such as atopic dermatitis, vitiligo and actinic keratosis. In addition to marketed therapies, Journey Medical maintains a development pipeline that includes novel small-molecule and biologic candidates, positioning the company to expand its presence in both established and emerging dermatology segments.

Headquartered in New York, Journey Medical conducts its commercial operations throughout the United States, leveraging strategic partnerships with contract manufacturers and specialty pharmacies to ensure broad product access. The company’s history of collaborations with global biopharmaceutical firms has enabled rapid regulatory submissions and efficient scale-up of manufacturing. Since its initial public offering in 2021, Journey Medical has strengthened its infrastructure to support future product launches and potential geographic expansion beyond North America.

Journey Medical is led by a management team with extensive experience in specialty pharmaceuticals, regulatory affairs and commercial execution. The company’s leadership emphasizes a patient-centric approach, collaborating with dermatologists and advocacy groups to identify unmet medical needs. By combining in-licensing expertise with agile development capabilities, Journey Medical aims to build a diversified dermatology franchise and deliver innovative therapies to healthcare professionals and patients nationwide.

Key Stats

• Today's Range: $7.17 to $7.48
• 50-Day Range: $5.97 to $8.07
• 52-Week Range: $3.54 to $8.25
• Volume: 64,122 shs
• Average Volume: 91,570 shs
• Market Capitalization: $167.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.50
• Consensus Rating: Buy

Journey Medical Stock Analysis - MarketRank™

Journey Medical scored higher than 45% of companies evaluated by MarketBeat, and ranked 636th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Journey Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Journey Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Journey Medical are expected to grow in the coming year, from ($1.02) to ($0.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Journey Medical is -18.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Journey Medical is -18.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Journey Medical has a P/B Ratio of 7.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.12% of the float of Journey Medical has been sold short.

Short Interest Ratio / Days to Cover

Journey Medical has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Journey Medical has recently increased by 79.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Journey Medical does not currently pay a dividend.

Dividend Growth

Journey Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.12% of the float of Journey Medical has been sold short.

Short Interest Ratio / Days to Cover

Journey Medical has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Journey Medical has recently increased by 79.08%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.29

News Sentiment

Journey Medical has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Journey Medical this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Journey Medical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Journey Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $52,606.00 in company stock.

Percentage Held by Insiders

15.03% of the stock of Journey Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.25% of the stock of Journey Medical is held by institutions.

DERM Stock Analysis - Frequently Asked Questions

How have DERM shares performed this year?

Journey Medical's stock was trading at $3.91 at the beginning of 2025. Since then, DERM shares have increased by 83.9% and is now trading at $7.19.

How were Journey Medical's earnings last quarter?

Journey Medical Corporation (NASDAQ:DERM) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06. The business had revenue of $13.14 million for the quarter, compared to the consensus estimate of $12.05 million. Journey Medical had a negative net margin of 14.76% and a negative trailing twelve-month return on equity of 52.03%.
Read the conference call transcript.

When did Journey Medical IPO?

Journey Medical (DERM) raised $39 million in an initial public offering on Friday, November 12th 2021. The company issued 3,520,000 shares at a price of $10.00-$12.00 per share.

How do I buy shares of Journey Medical?

Shares of DERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Journey Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Journey Medical investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Meta Platforms (META), ServiceNow (NOW), Adobe (ADBE) and AppLovin (APP).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DERM
• Previous Symbol: NASDAQ:DERM
• CIK: 1867066
• Web: journeymedicalcorp.com
• Phone: 480-434-6670
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Journey Medical: $9.50
• High Price Target: $10.50
• Low Price Target: $9.00
• Potential Upside/Downside: +32.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.67 million
• Net Margins: -14.76%
• Pretax Margin: -14.65%
• Return on Equity: -52.03%
• Return on Assets: -11.28%

Debt

• Debt-to-Equity Ratio: 1.07
• Current Ratio: 1.34
• Quick Ratio: 1.03

Sales & Book Value

• Annual Sales: $56.13 million
• Price / Sales: 2.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.91 per share
• Price / Book: 7.90

Miscellaneous

• Outstanding Shares: 23,300,000
• Free Float: 19,795,000
• Market Cap: $167.53 million
• Optionable: N/A
• Beta: 0.80